Income statement
USD
Annual
| Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 |
| Operating Income | -5M | -6M | -11M | -12M |
| EBITDA | -5M | -6M | -13M | -5M |
| Net Income | -9M | -10M | -20M | -10M |
| EPS (Diluted) | — | — | — | — |
Healthcare
Live Price
Offline$0.181
-28.74% today
1Y Change
-99.90%
Window
Jul 11, 2025 → Jun 18, 2026
Coverage: 236 bars · Jul 11, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Profusa, Inc. Common Stock (PFSA) is a Healthcare stock with listed on NASDAQ. The stock last traded around $0.18 and down 99.9% across the available one-year price window (Jul 11, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -409.6%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -409.6%, free cash flow -686.8% with operating margin 0.0% and ROIC 239.7%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PFSA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PFSA
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PFSA Max Drawdown
-99.90%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PFSA and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$10.3M
+49.0% YoY
Free Cash Flow
-$10.7M
-38.8% YoY
Revenue Growth
+0.0%
EPS Growth
-409.6%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 |
| Operating Income | -5M | -6M | -11M | -12M |
| EBITDA | -5M | -6M | -13M | -5M |
| Net Income | -9M | -10M | -20M | -10M |
| EPS (Diluted) | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Cash & Equivalents | 191K | 142K | 78K | 856K |
| Total Assets | 3M | 2M | 1M | 11M |
| Total Liabilities | 122M | 112M | 101M | 95M |
| Shareholder Equity | -119M | -110M | -100M | -84M |
| Total Debt | 48M | 40M | 31M | 24M |
| Net Debt | 48M | 40M | 31M | 23M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
11M
-38.8% YoY
Capital Expenditures
0
Free Cash Flow
11M
-38.8% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
81.8%
Debt / Equity
-0.56x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.